News & Updates
Showing Oncology articles
Showing

Rare gene mutations predict prostate cancer relapse
Rare and deleterious germline mutations affecting inflammatory response and cellular signaling pathways associate strongly with the time to biochemical recurrence (BCR) after radical treatment in patients with prostate cancer (PrCa), according to a recent study.

What causes death in bladder cancer patients?
Heart diseases, chronic obstructive pulmonary disease (COPD), concomitant cancers, and other co-occurring diseases elevate the risk of death in patients with nonmuscular invasive bladder cancer (NMIBC), nonmetastatic muscle invasive bladder cancer (non-MMIBC), and metastatic bladder cancer (MBC), according to a recent study.

Nintedanib falls short in bladder cancer trial
In the phase II NEOBLADE* trial, the addition of the multikinase** inhibitor nintedanib to neoadjuvant chemotherapy (CT) consisting of gemcitabine and cisplatin failed to improve pathological complete response (pCR) and progression-free survival (PFS) in individuals with locally advanced muscle-invasive bladder cancer (MIBC).

Ceritinib shows therapeutic potential in ALK-positive nonsmall cell lung cancer
The anaplastic lymphoma kinase (ALK) inhibitor ceritinib delivers favourable antitumour activity in ALK-mutated nonsmall cell lung cancer (NSCLC) patients with active brain metastases and/or leptomeningeal disease, according to the phase II ASCEND-7 trial.




